This makes economic sense. A Social Security number has clear, transferable value on the dark web. A medication list? Not so much. Clinical data depreciates quickly, requires specialized buyers, and has no obvious payoff in most cases.<\/p>\n
Yet under current U.S. regulations, all protected health information (PHI) is treated the same. HIPAA offers equal protection to a vaccination history and a billing address. That blanket approach has serious consequences.<\/p>\n
By treating all PHI as equally sensitive, current policy discourages legitimate and often life-saving data sharing. Hospitals are reluctant to share clinical records with specialists. Researchers run into hurdles accessing patient outcomes data. Public health agencies face delays in getting the information they need to track disease and target interventions.<\/p>\n<\/p>\n
Even when data sharing is technically allowed under HIPAA \u2014 such as for treatment or operational improvement \u2014 fear of regulatory reprisal often leads institutions to err on the side of caution. That includes declining to participate in health information exchanges, limiting collaboration with research networks, or hesitating to share even deidentified data. In California, liability and cybersecurity concerns have slowed participation in the state\u2019s new health data exchange framework, particularly among smaller and unaffiliated providers.<\/p>\n
The result is a chilling effect on data sharing \u2014 even in moments of national crisis. During the Covid-19 pandemic, for example, only 38% of hospitals surveyed by the American Hospital Association<\/a> agreed that they could electronically receive the patient information they needed from outside providers to effectively treat Covid-19 cases.<\/p>\n This overcaution can be dangerous. If a patient arrives unconscious in an emergency room, providers may not have access to their allergy list, past surgeries, or medication history \u2014 not because the data doesn\u2019t exist, but because it can\u2019t be easily shared. Rather than streamline care, privacy rules have, in many cases, paralyzed it.<\/p>\n The regulatory overreach also stifles innovation. As AI tools become increasingly central to health care \u2014 from diagnosing rare diseases to managing chronic conditions \u2014 they require large, diverse, and detailed datasets to function effectively. But because clinical data is treated with the same sensitivity as financial data, access for model training and validation is heavily restricted, even when all identifying information is removed. While concerns about re-identification are valid, current policies often overcorrect, limiting the potential of these tools to improve care.<\/p>\n Meanwhile, patients are already turning to large language models like ChatGPT for basic medical questions. With better data, these tools could level the playing field \u2014 offering more accurate guidance to underserved populations, improving early detection, and reducing misdiagnosis. But only if we can responsibly train them on real-world health data.<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/AdobeStock_1118287949-768x432.jpeg\")
\t\t<\/p>\n![\"\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/home\/statplus.svg\")